Balance of ruxolitinib to anti-GVHD and GVL effect after allo-HSCT
10.3760/cma.j.issn.0254-1785.2018.06.003
- VernacularTitle:Allo-HSCT后芦可替尼抗移植物抗宿主病与抗白血病复发的作用
- Author:
Sihua DANG
1
;
Qin LIU
;
Zhaodong ZHONG
;
Yong YOU
;
Jieke CUI
;
Lin JIANG
;
Na SHEN
;
Rong XIE
;
Shu ZHOU
;
Wen LIU
;
Ping ZOU
Author Information
1. 华中科技大学同济医学院附属协和医院血液科
- Keywords:
Hematopoietic stem cell transplantation;
Ruxolitinib;
JAK-STAT pathway;
Graft-versus-host disease;
Graft-versus-leukemia
- From:
Chinese Journal of Organ Transplantation
2018;39(6):333-337
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the anti-relapse and anti-graft versus host disease (GVHD) effects and side effects of ruxolitinib on patients who have relapsed leukemia after allo-hematopoietic stem cell transplantation (HSCT).Methods The clinical data of four patients sufferring from relapsed leukemia were collected and analyzed retrospectively.Three cases had a positive gene and 1 case had a extramedullary recurrence.All of them had serious GVHD involving multiparts,as the result of attenuating immunosuppressant aggressively.One case had central nervous system leukemia before allo-HSCT.Those patients were treated with ruxolitinib,according to the degree of GVHD,the treatment strategy and curative effect of GVHD,and the residual condition of original leukemia.Then,the degree of GVHD,the residual condition of original leukemia and the side effects of ruxolitinib were revaluated once a month after taking ruxolitinib.Results One case achieved completer remission (CR) and there partial remission (PR) in consideration of GVHD.Up to date,2 cases had no relapse in any level and 2 cases replased according to any of the results related to bone marrow aspiration.Conclusion Ruxolitinib is effective in patients with GVHD after allo-HSCT and doesn't influence GVL effect or increase the risk of relapse at the same time.Ruxolitinib doesn't have obvious side effects when treating GVHD.
